Drugs /

cabozantinib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
cabozantinib
Trade Name(s):
Cometriq
NCI Definition [1]:
An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for cabozantinib

Cabozantinib has been investigated in 91 clinical trials, of which 80 are open and 11 are closed. Of the trials investigating cabozantinib, 16 are phase 1 (15 open), 10 are phase 1/phase 2 (8 open), 52 are phase 2 (44 open), 12 are phase 3 (12 open), and 1 is phase 4 (1 open).

MET Amplification, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for cabozantinib clinical trials.

Clear cell renal cell carcinoma, renal cell carcinoma, and hepatocellular carcinoma are the most common diseases being investigated in cabozantinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cabozantinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cabozantinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cabozantinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
xl184, Cometriq, cabozantinib, n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, cabozantinib, cabozantinib (substance), 1,1-cyclopropanedicarboxamide, n'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- fluorophenyl)-
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
AXL, FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK2, RET, ROS1, TEK
NCIT ID [1]:
C52200
SNOMED ID [1]:
R0-00142

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.